{
    "clinical_study": {
        "@rank": "137770", 
        "acronym": "POLARIS", 
        "arm_group": {
            "arm_group_label": "Group1"
        }, 
        "brief_summary": {
            "textblock": "POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with\n      central involvement to assess the effectiveness of existing anti-vascular endothelial growth\n      factor (anti-VEGF) treatment regimens."
        }, 
        "brief_title": "Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ophthalmology", 
            "Macular Edema", 
            "Macular Degeneration"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Degeneration", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with type 1 or 2 diabetes mellitus\n\n          -  Patients diagnosed with DME with central involvement (defined as the area of the\n             center subfield of optical coherence tomography [OCT])\n\n          -  Patients for whom the decision has been made to treat with an approved anti-VEGF\n             therapy prior to inclusion into the study\n\n          -  Patients who received the first approved intravitreal anti VEGF treatment from\n             October 01, 2012\n\n          -  Patients who give informed consent in writing for study participation\n\n        Exclusion Criteria:\n\n          -  Treatment with any anti-VEGF therapy prior to the start of the observation period\n             (October 01, 2012) or enrolment into the study\n\n          -  Participation in an investigational program with interventions out of clinical\n             routine practice"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "In- and outpatients at participating sites with a diagnosis of DME with central\n        involvement. Patients will be enrolled after the decision for treatment with an approved\n        anti-VEGF therapy has been made at or after October 2012 by the study physician."
            }
        }, 
        "enrollment": {
            "#text": "807", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771081", 
            "org_study_id": "16459", 
            "secondary_id": "NN1201"
        }, 
        "intervention": {
            "arm_group_label": "Group1", 
            "description": "Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment", 
            "intervention_name": "Ranibizumab (or other DME treatment)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Endothelial Growth Factors"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Longitudinal Studies,", 
            "Observation", 
            "Epidemiology"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "France"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Greece"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Italy"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Portugal"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Slovakia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Spain"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Greece", 
                "Italy", 
                "Portugal", 
                "Russian Federation", 
                "Slovakia", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "POLARIS: A Non-interventional Study in Patients With Diabetic Macular Edema (DME) With Central Involvement to Assess the Effectiveness of Existing Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment Regimens", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: National Board of Physicians (C.N.O.M \"Comit\u00e9 National de l'Ordre des M\u00e9decins)", 
                "Germany: Ethics Committee", 
                "UK: UK Research Ethics Committee, UK National Health Service, Research and Development Department at each site", 
                "Italy: Ethics Committee, Italian Authority for Privacy and data Protection (Garante per la Privacy)", 
                "Portugal:Ethics Committee", 
                "Russia: Ethics Committee", 
                "Spain: Ethics Committee", 
                "Slovac Republic: Ethics Committee", 
                "Greece: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes in visual acuity, assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) or SNELLEN", 
            "safety_issue": "No", 
            "time_frame": "Baseline, after 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Demographic and clinical characteristics (Age, sex, race, employment status, severity of DME)", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Mean time from diagnosis to first commencement with an approved anti-VEGF therapy", 
                "safety_issue": "No", 
                "time_frame": "Date of first diagnosis; Date of treatment initiation: up to 24 month"
            }, 
            {
                "measure": "Changes in retinal thickness, measured by Optical Coherence Tomography (OCT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, after 12 month"
            }, 
            {
                "measure": "Presence of clinically significant macular edema, measured as defined by the ETDRS Research Group", 
                "safety_issue": "No", 
                "time_frame": "Baseline, after each month, up to 12 month"
            }, 
            {
                "measure": "Resource utilization in terms of treatment choices, frequency and duration", 
                "safety_issue": "No", 
                "time_frame": "Baseline, after 6 and 12 months"
            }, 
            {
                "measure": "Mean change in quality of life score (using the NEI VFQ 25), only in countries where used as part of routine practice", 
                "safety_issue": "No", 
                "time_frame": "Baseline, after 6 and 12 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}